CSIMarket
 
Schrodinger Inc   (NASDAQ: SDGR)
 
Price: $19.5300 $-0.50 -2.496%
Day's High: $20.0049991607666 Week Perf: -6.47 %
Day's Low: $ 19.25 30 Day Perf: 4.05 %
Volume (M): 159,064 52 Wk High: $ 23.02
Volume (M$): $ 0 52 Wk Avg: $16.06
Open: $19.88 52 Wk Low: $10.94



 Market Capitalization (Millions $) 1,480
 Shares Outstanding (Millions) 76
 Employees 850
 Revenues (TTM) (Millions $) 259
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) -70
 Capital Exp. (TTM) (Millions $) 4

Business Description


Schrodinger Inc is a leading computational chemistry and biophysics software company that was founded in 1990 by William Goddard III, Michael Levitt, and Peter Kollman. Schrodinger Inc is named after physicist Erwin Schrodinger, who was awarded the Nobel Prize in Physics in 1933 for his contribution to the development of quantum mechanics.

Schrodinger Inc is headquartered in New York City and has additional offices in Europe and Asia. The company is known for its state-of-the-art computational chemistry and biophysics software tools that enable scientists to accurately simulate and predict the behavior of molecules and other biological systems. These tools are used extensively in drug discovery, materials science, and development of biotechnology products.

The company's software platform, Schrodinger Suite, includes a range of software packages that help scientists perform a variety of tasks such as molecular dynamics simulations, ligand-based and structure-based drug design, and protein structure prediction. The software platform is also used to predict and understand the interactions of molecules with biological targets, allowing for more efficient drug discovery.

Schrodinger Inc has a diverse customer base, including academic and government research institutions, biotechnology and pharmaceutical companies, and chemical and materials manufacturers. The company's software tools have been used in several drug discovery projects that have led to the development of successful drugs, including the HIV protease inhibitor Saquinavir and the antipsychotic drug Aripiprazole.

Schrodinger Inc is also actively involved in scientific research and development. The company has a team of scientists who work on developing new software tools and applications, as well as collaborating with academic and industrial partners on various research projects.

Overall, Schrodinger Inc is a leading software company that has made significant contributions to the fields of computational chemistry and biophysics. The company's innovative software tools have played an important role in advancing drug discovery, materials science, and biotechnology, and will continue to be a major force in the scientific community for years to come.


   Company Address: 1540 Broadway New York 10036 NY
   Company Phone Number: 295-5800   Stock Exchange / Ticker: NASDAQ SDGR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CUE        10% 
ABSI   -1.47%    
CERT   -6.67%    
RVTY   -3.33%    
RXRX        2.85% 
SLP        0.08% 
• View Complete Report
   



Business Update

Navigating Growth and Innovation Schrodingers Strategic Inducement Grants and Evolving Collaborations in Drug Discovery

Published Fri, Sep 19 2025 9:19 AM UTC

Schrodinger, Inc., a leader in pharmaceutical computational science, continues to make strategic moves that enhance its competitive edge in the rapidly evolving drug discovery landscape. Recent inducement grants and a significant expansion in collaboration with Ajax Therapeutics highlight the company’s dual focus on building a talented workforce and advancing its researc...

Business Update

Schrödinger Enhances Employee Compensation with Stock Grants as Financial Ratios Show Improvement,

Published Sat, Aug 16 2025 8:40 AM UTC

Schrödinger Inc. Reports New Employee Stock Grants Amid Improved Financial Ratios NEW YORK Schrödinger, Inc. (Nasdaq: SDGR) announced today the granting of restricted stock units (RSUs) as part of its ongoing strategy to attract and retain talent. On August 15, 2025, the biotechnology company granted RSUs representing 1,875 shares of its common stock to two newly hired...

Business Update

Ajax Therapeutics and Schrodinger Forge Ahead New JAK Inhibitors and Game-Changing Cancer Therapies on the...

Published Thu, Jul 17 2025 2:13 PM UTC

Expanding Horizons: Ajax Therapeutics and Schrodinger Enhance Collaboration to Target New JAK Inhibitors and Drive Innovation in Cancer Research In a significant advancement for drug development, Ajax Therapeutics, Inc. and Schrodinger, Inc. (Nasdaq: SDGR) have announced an expansion of their longstanding collaboration, now encompassing a new Janus kinase (JAK) target. This ...

Business Update

Schrodinger Set to Showcase Innovations at Key Investor Conferences in March 2025,

Published Mon, Feb 24 2025 8:43 PM UTC

: Schrodinger, a prominent leader in the field of computational drug discovery, has announced its participation in multiple investor conferences scheduled for March 2025. This engagement presents an opportunity for the company to discuss its groundbreaking developments in pharmaceutical sciences and computational chemistry with investors and industry stakeholders.Advancement...

Business Update

Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Published Tue, Nov 19 2024 3:56 PM UTC

Schrodinger Expands Its Talent Pool with Strategic RSU Grants Under Nasdaq Listing RuleIn a notable move to bolster its workforce and align with industry standards for employee compensation, Schrodinger, Inc. (Nasdaq: SDGR) has disclosed the granting of restricted stock units (RSUs) to four newly hired employees. This announcement, made on November 14, 2024, expands upon Sc...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.71
Price to Sales (Expected) -
Price to Book 4.5
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.38
Working Capital Ratio 2.56
Leverage Ratio (MRQ) 0.95
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.74 $
Revenues (TTM) 3.42 $
Cash Flow (TTM) -
Cash 5.46 $
Book Value 4.34 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 304,747
Net Income per Employee (TTM) -63,924
Receivable Turnover Ratio (TTM) 6.43
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.38

Profitability Ratios Current
Gross Margin (MRQ) 55.07 %
Operating Margin (MRQ) -70.55 %
Net Margin (MRQ) 10.15 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Schrodinger Inc's Segments
Software products and services    115.65 % of total Revenue
Drug discovery    39.87 % of total Revenue
Contribution    5.96 % of total Revenue
Hosted software    46.24 % of total Revenue
Novartis Pharma AG Drug Discovery Services Collaboration And License Agreement    19.6 % of total Revenue
Professional services    4.96 % of total Revenue
Bristol Myers Squibb Oncology Neurology And Immunology Product    1.05 % of total Revenue
APAC    22.71 % of total Revenue
Software    120.61 % of total Revenue
United States    117.06 % of total Revenue
EMEA    58.67 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.